13 / 25
Page 57
allied
academies
September 20-22, 2017 | Toronto, Canada
10
TH
AMERICAN PEDIATRICS HEALTHCARE &
PEDIATRIC INFECTIOUS DISEASES CONGRESS
Pediatric Healthcare & Pediatric Infections 2017
A
dvances in new therapies for childhood cancer have
resulted in cure rates of almost 80%. But there is greater
risk for developing late adverse effects after treatment,
including obesity, high blood pressure, cardiovascular
diseases,andimpairedglucosemetabolism.Endocrinopathies
are among the most frequently encountered late sequelae
in Cancer Childhood Survivors (CCS). Some of mentioned
adverse effects are part of metabolic syndrome (MetS).
Although the exact relation between cancer and MetS is
not elucidated yet, but treatment factors (radiotherapy,
chemotherapy) have been indicated to determine metabolic
changes in CCS rather than baseline characteristics. Obesity
is another concern in these patients which is reported to
be higher among Acute Lymphoblastic Leukemia and brain
tumors survivors. Obesity in situ can lead to inflammation as
described in literature and also has considerable endocrine
changes because of adipokines like Leptin and Adiponectin
and others. Glucocorticoids treatment is one of risk factors
in CCS. Impaired glucose tolerance because of osteocalcin
dysregulation is another hormonal change which can cause
harmful phenomenon like Insulin resistance. Undoubtedly
nutrition has remarkable effect for management of these
disorders. Based on child characteristics, type of cancer,
type of therapy and present disorder, different management
needs to be planned. Some of nutritional intervention
aim to increase insulin sensitivity and some of them to
prevent or treat obesity. So we wish we can explain these
endocrinopathies and also nutrition management.
e:
Hesam.es.sh@gmail.comLong-term endocrine effects of chemotherapy in cancer childhood survivors
Hesam Eshaghi
1
and
Ehsan Ghaedi
2
1
Tehran University of Medical Sciences, Iran
2
Ahvaz Jundishapur University of Medical Sciences, Iran